Patient competence in allergic diseases of the atopic form: a randomised controlled trial on the effectiveness of a newly developed digital platform for people with mild to moderate allergic symptoms

Patient competence in allergic diseases of the atopic form: a randomised controlled trial on the effectiveness of a newly developed digital platform for people with mild to moderate allergic symptoms - PAKO-ATOP

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

DRKS

Registry ID

DRKS00021253

Enrollment

600

Registered

2020-04-24

Start date

2020-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T78.4 J45.0 L20.0

Interventions

Group 1: The intervention group (adults with allergic diseases of the atopic form, light-medium symptoms) has the possibility to work on all developed learning modules of the learning platform "Self a

Eligibility

Sex/Gender

All

Age

18 Years to 76 Years

Inclusion criteria

Inclusion criteria: medically confirmed allergic disease of the atopic form (allergy (pollen, house dust, animal hair, food), allergic asthma, neurodermatitis) with mild to moderate symptoms

Exclusion criteria

Exclusion criteria: no allergic disease of the atopic form; younger than 18 years; older than 76 years; severe symptoms requiring regular medical treatment

Design outcomes

Primary

Measure	Time frame
Improvement of knowledge about disease and treatment in patients with mild and moderate allergic symptoms. The target values are recorded online in both groups with standardised survey instruments and at the following measurement times: T0: at the beginning of the intervention: CARAT (asthma control); MAuI-ALL (sociodemographic data); SES6G (self-efficacy); SF-12-SOEP (health-related quality of life); WPAI+CIQ:AS (impairments) as well as knowledge questions, disease-specific and sociodemographic data. T1: Start of the 5th week after T0, "intensive week" with daily recording of allergic symptoms (CARAT) over five days T2: after 8 weeks: CARAT and knowledge questions T3: after 12 weeks: MAUI-ALL; SES6G; SF-12-SOEP; WPAI+CIQ:AS and knowledge questions. CARAT = The Control of Allergic Rhinitis and Asthma Test MAuI-ALL = My allergy and me SES6G = Self-Efficacy for Managing Chronic Disease 6-Item Scale SF12 SOEP = Standard Values for Physical and Mental Health Scale Scores WPAI = Work Productivity and Activity Impairment Questionnaire	—

Measure

Time frame

Improvement of knowledge about disease and treatment in patients with mild and moderate allergic symptoms. The target values are recorded online in both groups with standardised survey instruments and at the following measurement times: T0: at the beginning of the intervention: CARAT (asthma control); MAuI-ALL (sociodemographic data); SES6G (self-efficacy); SF-12-SOEP (health-related quality of life); WPAI+CIQ:AS (impairments) as well as knowledge questions, disease-specific and sociodemographic data. T1: Start of the 5th week after T0, "intensive week" with daily recording of allergic symptoms (CARAT) over five days T2: after 8 weeks: CARAT and knowledge questions T3: after 12 weeks: MAUI-ALL; SES6G; SF-12-SOEP; WPAI+CIQ:AS and knowledge questions. CARAT = The Control of Allergic Rhinitis and Asthma Test MAuI-ALL = My allergy and me SES6G = Self-Efficacy for Managing Chronic Disease 6-Item Scale SF12 SOEP = Standard Values for Physical and Mental Health Scale Scores WPAI = Work Productivity and Activity Impairment Questionnaire

—

Secondary

Measure	Time frame
Strengthening the ability to act and self-management; strengthening the conviction of control; increasing the quality of life. The target values are recorded online in both groups with standardised survey instruments and at the following measurement times: T0: at the beginning of the intervention: CARAT (asthma control); MAuI-ALL (sociodemographic data); SES6G (self-efficacy); SF-12-SOEP (health-related quality of life); WPAI+CIQ:AS (impairments) as well as knowledge questions, disease-specific and sociodemographic data. T1: Start of the 5th week after T0, "intensive week" with daily recording of allergic symptoms (CARAT) over five days T2: after 8 weeks: CARAT and knowledge questions T3: after 12 weeks: MAUI-ALL; SES6G; SF-12-SOEP; WPAI+CIQ:AS and knowledge questions. CARAT = The Control of Allergic Rhinitis and Asthma Test MAuI-ALL = My allergy and me SES6G = Self-Efficacy for Managing Chronic Disease 6-Item Scale SF12 SOEP = Standard Values for Physical and Mental Health Scale Scores WPAI = Work Productivity and Activity Impairment Questionnaire	—

Measure

Time frame

Strengthening the ability to act and self-management; strengthening the conviction of control; increasing the quality of life. The target values are recorded online in both groups with standardised survey instruments and at the following measurement times: T0: at the beginning of the intervention: CARAT (asthma control); MAuI-ALL (sociodemographic data); SES6G (self-efficacy); SF-12-SOEP (health-related quality of life); WPAI+CIQ:AS (impairments) as well as knowledge questions, disease-specific and sociodemographic data. T1: Start of the 5th week after T0, "intensive week" with daily recording of allergic symptoms (CARAT) over five days T2: after 8 weeks: CARAT and knowledge questions T3: after 12 weeks: MAUI-ALL; SES6G; SF-12-SOEP; WPAI+CIQ:AS and knowledge questions. CARAT = The Control of Allergic Rhinitis and Asthma Test MAuI-ALL = My allergy and me SES6G = Self-Efficacy for Managing Chronic Disease 6-Item Scale SF12 SOEP = Standard Values for Physical and Mental Health Scale Scores WPAI = Work Productivity and Activity Impairment Questionnaire

—

Countries

Germany

Contacts

Public ContactKarin Drixler

Pädagogische Hochschule Freiburg

karin.drixler@ph-freiburg.de0711-682-258

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026